Department of Pulmonary and Critical Care Medicine, Centre of Respiratory Medicine, China-Japan Friendship Hospital; National Clinical Research Centre for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, 2 Yinghuayuan East Street, Chaoyang District, Beijing, 100029, China.
Department of Pathology, China-Japan Friendship Hospital, Beijing, 100029, China.
BMC Pulm Med. 2020 Jun 29;20(1):183. doi: 10.1186/s12890-020-01203-w.
Identification of pathologic features is helpful for the management of nonresolving acute respiratory distress syndrome (ARDS). Transbronchial lung cryobiopsy (TBLC) is a novel biopsy technique that may have comparable utility to surgical biopsy. The aim of this study was to assess the value of TBLC in patients with nonresolving ARDS.
All patients with nonresolving ARDS who underwent TBLC from January 2019 to August 2019 in a tertiary medical ICU were included. In addition, a literature search of TBLC for ARDS was performed by searching PubMed, EMBASE, ATS/ERS/APSR meeting abstracts, ClinicalTrials.gov , and Google Scholar. Data on complications, histologic diagnosis, management changes, and outcomes were analysed.
Five patients (three women and two men) underwent TBLC. None of the patients developed pneumothorax, although two patients developed massive bleeding, which was controlled by continuous occlusion using bronchial blockers. There were no procedure-related deaths. Diffuse alveolar damage (DAD) and alternative histologic patterns were found in two and three patients, respectively, resulting in management changes in all cases. The literature search yielded four studies, which together with the present study comprised data from 25 cases in which TBLC was used in nonresolving ARDS. The summary diagnostic yield was 92% (23/25). Only 44% (11/25) of cases were proven to be DAD. TBLC contributed to management changes in 80% of patients (20/25). Procedure-related complications consisted of pneumothorax (16%, 4/25), significant bleeding (12%, 3/25), and persistent air leaks (8%, 2/25). There were no procedure-related deaths. The follow-up survival rate was 61.9% (13/21).
The complications of TBLC in selected patients with nonresolving ARDS may be acceptable. The procedure may have a high diagnostic yield and can lead to a re-evaluation of the diagnosis as well as changes in patient management. Further investigations with larger sample sizes are required.
病理性特征的识别有助于非解析性急性呼吸窘迫综合征(ARDS)的管理。经支气管肺冷冻活检(TBLC)是一种新的活检技术,其可能与外科活检具有同等的效用。本研究旨在评估 TBLC 在非解析性 ARDS 患者中的价值。
纳入 2019 年 1 月至 2019 年 8 月在一家三级医疗 ICU 接受非解析性 ARDS 行 TBLC 的所有患者。此外,通过检索 PubMed、EMBASE、ATS/ERS/APSR 会议摘要、ClinicalTrials.gov 和 Google Scholar 对 ARDS 的 TBLC 进行了文献检索。分析了并发症、组织学诊断、治疗改变和结局数据。
5 名患者(3 名女性和 2 名男性)接受了 TBLC。尽管 2 名患者发生大量出血,但均通过使用支气管阻塞器连续闭塞来控制,没有发生气胸。无与操作相关的死亡。2 名患者分别发现弥漫性肺泡损伤(DAD)和替代组织学模式,所有病例均发生治疗改变。文献检索共纳入 4 项研究,加上本研究共包括 25 例非解析性 ARDS 中使用 TBLC 的病例数据。总结诊断率为 92%(23/25)。仅 44%(11/25)的病例证实为 DAD。TBLC 使 80%的患者(20/25)的治疗发生改变。与操作相关的并发症包括气胸(16%,4/25)、明显出血(12%,3/25)和持续空气漏(8%,2/25)。无与操作相关的死亡。随访生存率为 61.9%(13/21)。
在选择的非解析性 ARDS 患者中,TBLC 的并发症可能是可以接受的。该操作可能具有较高的诊断率,并能导致对诊断的重新评估以及患者治疗的改变。需要进一步开展更大样本量的研究。